On March 24, 2026, the FDA granted 510(k) clearance to Livi, a single-use polyurethane foam device from New York-based startup LiviWell that absorbs semen and post-intercourse vaginal fluids. The clearance creates a new regulated product category in women's health — post-coital vaginal care — that has not previously existed as an approved medical device in the United States. Livi is scheduled to launch commercially at the end of May 2026 through direct-to-consumer online sales, with retail distribution planned afterwards.

Why It Matters

Livi is a test case for whether FDA medical-device framing can legitimize — and insurance-coverage — a product category that currently lives in the gray zone between feminine hygiene and sexual wellness. If LiviWell demonstrates commercial traction through the May 2026 launch and subsequent real-world data, the 510(k) pathway could become a playbook for other "post-intercourse care" products that have lived on Amazon's wellness shelf as unregulated commerce.

The device is inserted via a tampon-style applicator within 15 minutes of intercourse and absorbs fluid in approximately 60 seconds before being removed. LiviWell's clinical rationale, per chief medical officer Dr. Michael Ingber (a board-certified urogynecologist and co-founder), is that seminal fluid disrupts vaginal pH and contributes to common post-coital symptoms including odor, discharge, and conditions like bacterial vaginosis. The company positions Livi as a complement to, not a replacement for, condoms or other contraceptive measures — the device is specifically for fluid management after unprotected or barrier-contraception-failure encounters.

CEO Dawn Halkuff, a Tylenol and Glaxo alum who previously led CEOs at Tivic Health and TherapeuticsMD, leads the commercial side. LiviWell closed an oversubscribed $3.3 million seed round in 2024 to fund the FDA clearance pathway. The approval positions the company as the first entrant in a category that had been technically unaddressed; competing products like post-sex wipes, douches, and probiotic suppositories are either over-the-counter personal care or unregulated wellness products rather than FDA-cleared devices.

Industry reaction has been mixed. Obstetrics and gynecology trade publications including Contemporary OB/GYN have covered the clearance as a meaningful expansion of post-intercourse care options, particularly for patients with recurrent bacterial vaginosis. Critics — including independent OB/GYNs writing on Substack — have pushed back that the device may be a solution in search of a problem, given that vaginal self-cleaning mechanisms already handle most post-coital pH shifts in healthy patients. LiviWell's clinical data package submitted to FDA consisted of biocompatibility testing and absorption performance rather than outcome-based clinical trials demonstrating reduction in infection rates.

The clearance also lands in a regulatory environment where FDA has expanded several women's health pathways in Q1 2026: Flibanserin received expanded use approval for HSDD in postmenopausal women, the VYBRIQUE sildenafil oral film was approved for ED, and the agency removed black-box warnings on menopausal HRT. The Livi clearance is the smallest of these by clinical stakes but the most novel by category definition.

Sources

Update — 2026-04-22

Initial entry — story first created.

Update — 2026-05-19

Livi is shipping. LiviWell confirmed via its public-facing site (mylivi.com) and a refreshed press cycle this week that direct-to-consumer online sales are now live, with the commercial launch landing exactly to the "end of May 2026" timeline laid out at the time of FDA clearance. The launch is online-only at first — single applicators sold individually and in multi-packs of 6 and 12 — with retail distribution targeted for Q3 2026 alongside conversations with major drugstore chains and Target's sexual wellness aisle. Marketing positioning leans into the "first FDA-cleared post-intercourse care device" framing rather than the bacterial vaginosis–prevention angle, a notable softening that may be driven by FDA labeling constraints on outcome claims that weren't supported by clinical trial data in the original 510(k) submission. Early DTC pricing reportedly lands around $19.99 for a 6-pack, putting the per-use cost at roughly $3.33 — comparable to a name-brand condom but explicitly positioned as complementary rather than substitute. Industry observers will be watching three near-term signals: (1) D2C conversion rates and customer cost-of-acquisition data through the first 90 days; (2) whether OBGYN providers begin actively recommending Livi to recurrent-BV patients (FemTech Insider's editorial team flagged this as the make-or-break clinical adoption question); and (3) whether the 510(k) regulatory framing translates to insurance reimbursement or HSA/FSA eligibility, either of which would be a structural competitive advantage over the unregulated post-coital care market on Amazon.

New Sources